DelMar Pharmaceuticals Announces Reverse Stock Split in Preparation for Proposed Senior Exchange Uplisting
DelMar Pharmaceuticals Updates Ongoing Phase I/II Refractory GBM Clinical Trial with VAL-083 at AACR Annual Meeting
DelMar's VAL-083 Demonstrates Promise in the Treatment of Non-Small Cell Lung Cancer and Ovarian Cancer
DelMar Pharmaceuticals Announces Abstract Presentations for the American Association Cancer Research Annual Meeting in April 2016
DelMar Pharmaceuticals to Collaborate with MD Anderson Cancer Center on Development of DelMar's VAL-083 in Brain Cancer
DelMar Pharmaceuticals, Inc. – "Modernizing Medicines: DelMar’s Strategic Edge for VAL-083 in Oncology"
